Organization
AIVITA Biomedical
3 clinical trials
2 abstracts
Clinical trial
Adaptive Phase I-II Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 AntibodiesStatus: Withdrawn, Estimated PCD: 2023-06-01
Clinical trial
Randomized Phase 3 Trial of Standard Care Plus AV-GBM-1 vs Autologous Monocytes as Adjunctive Therapy Following Primary Surgery Plus Concurrent Radiation-temozolomide in Patients With Newly Diagnosed GlioblastomaStatus: Not yet recruiting, Estimated PCD: 2028-03-01
Clinical trial
Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-05-01
Abstract
Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).Org: University of California Irvine, University of California San Diego, University of California Irvine Department of Epidemiology and Biostatistics, Norton Cancer Institute, Rutgers Cancer Center,
Abstract
Randomized phase 2 trial of personal dendritic cell (DC)-autologous tumor antigen (ATA) vaccines in newly diagnosed advanced ovary cancer.Org: University of Colorado Cancer Center, Hoag Gynecologic Oncology, Scripps Clinic/Green Hospital, University of California San Diego, Moores Cancer Center, University of California Irvine,